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bjectives This study sought to evaluate the safety and efﬁcacy of a biodegradable polymer-coated
irolimus-eluting stent (Excel, JW Medical System, Weihai, China) with 6-month dual antiplatelet
herapy in daily practice.
ackground It has been hypothesized that persistent presence of polymer may compromise the
afety of drug-eluting stents, and that therefore biodegradable polymer coatings might reduce late
dverse events.
ethods Between June and November 2006, 2,077 patients, exclusively treated with Excel
tents at 59 centers from 4 countries, were enrolled in this prospective, multicenter registry.
ecommended antiplatelet regimen included clopidogrel and aspirin for 6 months followed by
hronic aspirin therapy.
esults The average duration of clopidogrel treatment was 199.8  52.7 days and 80.5% of dis-
harged patients discontinued clopidogrel at 6 months. The cumulative rates of major adverse car-
iac events were 0.9% at 30 days, 2.7% at 1 year, and 3.1% at 18 months. Overall rate of stent
hrombosis was 0.87% at 18 months. The rates of acute, subacute, late, and very late stent thrombo-
is were 0.1%, 0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974
31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss of 0.21  0.39
m. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment.
onclusions This multicenter registry documents satisfactory safety and efﬁcacy proﬁles, as evidenced
y low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biode-
radable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in
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CREATE]; NCT00331578) (J Am Coll Cardiol Intv 2009;2:303–9) © 2009 by the American College of
ardiology Foundation
rom the *Shenyang Northern Hospital, Shenyang, China; †Cardiovascular Institute and Fuwai Hospital, Beijing, China;
Kunming General Hospital of Chengdu Military Region, Kunming, China; §General Hospital of Armed Police Forces, Beijing,
hina; Tangshan Gongren Hospital, Tangshan, China; ¶Affiliated Hospital of Chinese People’s Armed Police Forces Medical
ollege, Tianjin, China; #The People’s Hospital of Liaoning Province, Shenyang, China; **Shanxi Provincial Corps Hospital of
hinese People’s Armed Police Forces, Xi’an, China; ††Daqing Oilfields General Hospital, Daqing, China; ‡‡Guangzhou Army
eneral Hospital, Guangzhou, China; and the §§Zhujiang Hospital of Southern Medical University, Guangzhou, China.
upported by a grant from JW Medical System, Weihai, China.anuscript received October 14, 2008; revised manuscript received December 9, 2008, accepted December 21, 2008.
A
t
b
t
b
t
u
t
c
D
p
p
p
d
w
l
t
“
M
P
o
r
s
d
w
i
I
s
d
t
a
H
i
i
i
S
(
(
s
0
m
9
S
f
h
d
t
a
T
a
A
a
e
a
m
h
p
O
m
(
r
l
t
p
d
d
o
l
d
e
m
n
t
n
i
p
S
p
R
h
v
t
t
i
t
A
a
D
M
c
M
P
S
s
T
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 4 , 2 0 0 9
A P R I L 2 0 0 9 : 3 0 3 – 9
Han et al.
Biodegradable Polymer-Coated DES
304lthough first-generation drug-eluting stents (DES) were
outed as a major breakthrough in interventional cardiology
ecause of their efficacy in reducing in-stent restenosis and
arget lesion revascularization (TLR) rates compared with
are-metal stents (1–3), the initial enthusiasm has been
empered by concerns about their long-term safety, partic-
larly numerically higher rates of late and very late stent
hrombosis, which have been associated with catastrophic
onsequences (4–7).
See page 310
The mechanisms of late or very late stent thrombosis after
ES implantation have not yet been clarified, but the stent
latform design, the toxicity of active drug and the durable
olymer coatings are considered potentially relevant to this
roblem. Several histopathological studies indicated that the
urable polymer coatings of DES, which were associated
ith hypersensitivity reactions directed against the polymer,
ocalized vascular inflammation, apoptosis of smooth muscle
cells, and thrombogenic reac-
tions, may play important roles
in late or very late stent throm-
bosis (8–11). Based on this con-
sideration, biodegradable poly-
mer coatings have been used in
some new generation DES, in-
cluding the Excel stent (JW Med-
ical System, Weihai, China). In
the present study, we sought to
evaluate the long-term safety
and efficacy of the Excel stent in
the context of 6-month dual an-
iplatelet therapy for the treatment of coronary lesions in
real-world” practice.
ethods
atient enrollment. The CREATE (Multi-Center Registry
f Excel Biodegradable Polymer Drug Eluting Stents)
egistry is a post-marketing surveillance multicenter, pro-
pective study. Between June and November 2006, multiple
emographic, clinical, angiographic, and follow-up variables
ere collected for patients receiving successful Excel stent
mplantation at 59 medical centers from 4 countries (China,
ndonesia, Malaysia, and Thailand). The indications for
tenting were left to the operators’ discretion. Patients with
evice or procedural failure, who received 1 stent other
han the protocol stent, or had contraindications for dual
ntiplatelet therapy, heart function worse than New York
eart Association functional class III, or a planned upcom-
bbreviations
nd Acronyms
ES  drug-eluting stent(s)
ACE  major adverse
ardiac event(s)
I  myocardial infarction
LA  polylactic acid
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularizationng surgery were excluded. Ethics committees in all partic- opating centers approved the study protocol, and a signed,
nformed consent was obtained from every enrolled patient.
tent features. The Excel stent is a sirolimus-eluting stent
SES) that is coated with a biodegradable polylactic acid
PLA) polymer. The stent platform is a laser-cut, 316L
tainless steel, open cell design stent with strut thickness of
.0047 inches. The PLA coating used in the Excel stent is
ixed with sirolimus (C51H79NO13, molecular weight
14.2) (North China Pharmaceutical Group Corporation,
hijiazhuang, China) and coated onto the abluminal sur-
aces of the stent to a thickness of 10 to 15 m. The coating
as been shown in animal studies to have a complete
egradation cycle of 6 to 9 months (based on communica-
ions with JW Medical System, October, 2007). There is no
dhesive surface between the polymer and the stent struts.
otal sirolimus dosage varies from 195 to 376 g per stent
ccording to the stent length.
ntithrombotic therapy. Loading doses of aspirin (300 mg)
nd clopidogrel (300 mg) were given at least 24 h before
lective procedures, followed by maintenance dosages of
spirin of 100 mg per day indefinitely and clopidogrel of 75
g per day for 6 months. Use of low-molecular weight
eparin and glycoprotein IIb/IIIa inhibitors during the
eriprocedure period was left to operators’ discretion.
utcomes, deﬁnitions, and follow-up. The predefined pri-
ary outcome was rate of major adverse cardiac events
MACE) at 12 months after Excel stent implantation in
eal-world practice. Secondary outcomes were in-stent late
umen loss and binary restenosis at 9 months, and cumula-
ive thrombotic event rates up to 18 months after the index
rocedure. We defined MACE as a composite of cardiac
eath, nonfatal myocardial infarction (MI), and TLR. All
eaths were considered to be cardiac unless a noncardiac
rigin could be clearly established by clinical and/or patho-
ogical study. The diagnosis of MI was based on either the
evelopment of new pathological Q waves in2 contiguous
lectrocardiogram leads and/or elevation of creatine kinase-
yocardial band isoenzyme level 3 times the upper
ormal limit after the procedure during index hospitaliza-
ion, or cardiac enzyme level elevation 2 times the upper
ormal limit thereafter. We defined TLR as any repeat
ntervention inside the stent implanted during the index
rocedure or within 5 mm proximal or distal to the stent.
tent thrombosis was classified as definite, probable, and
ossible according to definitions proposed by the Academic
esearch Consortium (12); it was stratified as acute (24
), subacute (24 h to 30 days), late (30 days to 1 year), and
ery late (1 year). Off-label indications included lesions
hat did not meet the manufacturer’s instructions for use for
he Cypher SES (Cordis Corporation, Miami Lakes, Flor-
da), as well as patients with acute MI or who had lesions in
he left main coronary artery or ostial, bifurcated, or totally
ccluded lesions.
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305Clinical follow-ups, by office appointment or phone call,
ere scheduled at 1, 3, and 6 months, and every 6 months
hereafter up to 3 years. Angiographic follow-up was per-
ormed 6 to 12 months after the index procedure or earlier
f clinically indicated. The anticipated angiographic
ollow-up rate was 35%.
ata collection and management. Clinical data were pro-
pectively collected on case-report forms and submitted to a
ata coordination center (located at Shenyang Northern
ospital). The consistency and accuracy of the data, includ-
ng baseline, in-hospital, and follow-up outcomes, were
udited by independent study monitors. At least 15% of
atients in each center were randomly selected for audit
heck. If a discrepancy between the case-report form versus
ource documentation was found, all data from the center
as audited. A total of 332 patients from 56 centers were
elected for audit check, accounting for 16.0% of all enrolled
atients. All adverse clinical events were reviewed and
djudicated by an independent clinical events committee.
he overall data accuracy rate was 99.4% (330 of 332),
ecause 2 patients underwent non-TLR that was reported
s MACE.
Visual estimation of lesion characteristics in relation to
hose in the index procedure was performed by the operator
nd recorded. If a patient underwent angiographic follow-
p, coronary angiograms obtained at baseline, procedure
ompletion, and follow-up were submitted to the indepen-
ent angiographic core laboratory (Catheterization Lab,
ardiovascular Institute and Fu Wai Hospital, Beijing,
hina). Quantitative coronary angiography was performed
ith Quantcor QCA (CAAS II) version 5.0 (Pie Medical
maging, Maastricht, the Netherlands). Binary restenosis
as defined as 50% diameter stenosis at follow-up and
as classified as in-stent if inside of the stent or in-segment
f located at the stented segment or up to 5 mm proximal or
istal to the stents. Late lumen loss was defined as the
ifference between the minimal lumen diameter immedi-
tely after the procedure and at follow-up.
tatistical analysis. Comparisons between continuous vari-
ble data, expressed as mean  SD, were performed with
he t test, while the chi-square or the Fisher exact tests were
sed for categorical data, expressed as percentages. The
ACE-free survival curve was calculated by the Kaplan-
eier method. Statistical analyses were performed with the
PSS 12.0 software (SPSS, Inc., Chicago, Illinois). A p
alue of 0.05 was considered statistically significant.
esults
atient sample and baseline characteristics. Data for 2,077
atients in the registry were analyzed, representing 95.1% of
,183 consecutive patients. We excluded 90 patients (4.1%)
ecause of hybrid stenting with other DES types and 16
0.7%) patients because of failure to deliver the stent. The oean age of the cohort was 60.6  11.1 years, 73.6% were
en, and 21.2% were diabetics. Baseline characteristics are
urther detailed in Table 1.
ngiographic and procedural characteristics. A total of
,080 target lesions were treated, including 26 (0.8%)
nprotected left main, 667 (21.7%) bifurcation, 76 (2.5%)
hronic total occlusion, 69 (2.2%) restenotic, and 1,309
42.5%) diffusely diseased lesions. Multivessel stenting was
erformed in 26.9% of patients and 84.5% of enrolled
atients had at least 1 off-label indication for DES implan-
ation. A total of 3,748 Excel stents were implanted at index
rocedure (1.8 stents per patients) with an average diameter
nd total stent length of 3.05 0.44 mm and a 26.7 13.0
m, respectively. A total of 52.4% of all stents were
mplanted without pre-dilation. Major angiographic and
rocedural characteristics are shown in Table 2.
ntiplatelet therapy. At time of discharge, all surviving
atients were being treated with aspirin and clopidogrel
xcept for 1 patient in whom all antiplatelet therapy was
iscontinued because of thrombocytopenia. Data on dual
ntiplatelet treatment status from 2,053 discharged patients
ere obtained. The mean duration of dual antiplatelet
herapy was 199.8 52.7 days. Out of 2,053 patients, 1,652
80.5%) discontinued clopidogrel treatment at 6 months
fter their index procedures. The other 401 patients (19.5%)
ad their clopidogrel treatment extended to 7 to 12 months.
linical outcomes. Clinical follow-up was completed in
,077 (100%) patients at 30 days, 2,063 (99.3%) at 1 year,
nd 2,062 (99.3%) at 18 months, respectively. Primary
vents developed in 56 patients (2.7%) at 1 year, consisting
Table 1. Baseline Characteristics
Parameters n  2,077
Age (yrs) 60.6  11.1
Male 1,528 (73.6)
Risk factors
Smoker 1,041 (50.1)
Prior MI 234 (11.3)
Hypertension 1,157 (55.7)
Diabetes 440 (21.2)
Hyperlipidemia 624 (30.0)
Peripheral or cerebral vascular disease 356 (17.1)
Family history of coronary heart disease 158 (7.6)
Indications for index procedure
Silent ischemia 81 (3.9)
Stable angina 131 (6.3)
Unstable angina 1,105 (53.2)
AMI within 24 h 386 (18.6)
Recent MI (24 h to 30 days) 374 (18.0)
Cardiogenic shock 22 (1.1)
Data are expressed as mean SD or n (%).
AMI acute myocardial infarction; MImyocardial infarction.f 22 (1.1%) cardiac deaths, 8 (0.4%) nonfatal MIs, and 32
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3061.6%) TLRs. At 18-month clinical follow-up, 39 patients
1.8%) had died, including 23 patients (1.1%) who died of
ardiac reasons. The rates of MACE, MI, and TLR at
8-month follow-up were 3.1% (64 of 2,062), 0.4% (9 of
,062), and 1.9% (39 of 2,062), respectively. The 30-day,
-year, and 18-month adverse clinical events are shown in
able 3. The 18-month MACE-free survival curve is
llustrated in Figure 1.
At the 18-month follow-up, stent thromboses had devel-
ped in 18 patients (0.87%), including 2 (0.1%) acute, 8
0.38%) subacute, 7 (0.34%) late, and 1 (0.05%) very late
tent thromboses. Another 4 (0.19%) out of 8 late or very
ate stent thromboses developed at 4, 31, 130, and 198 days
fter clopidogrel discontinuation, respectively, while the
ther 4 stent thromboses occurred during treatment with
lopidogrel. The occurrence of Academic Research Consor-
ium definite or probable stent thromboses was 0.58% (12 of
,063). Further details are shown in Table 4.
Univariate analyses showed that male sex (odds ratio
OR]: 2.508, 95% confidence interval [CI]: 1.173 to 5.359;
 0.007), acute MI within 24 h (OR: 1.895, 95% CI:
.113 to 3.226; p  0.017), 2 stents implanted (OR:
.191, 95% CI: 1.252 to 3.836; p  0.005), and multivessel
tenting (OR: 2.426, 95% CI: 1.421 to 4.139; p  0.001)
Table 2. Angiographic and Procedural Characteristics
Multivessel stenting 558 (26.9)
Off-label use 1,756 (84.5)
No. of target vessels 2,717
No. of target lesions 3,080
Average reference vessel diameter, mm 3.0  0.46
Average lesion length, mm 22.3  13.1
Average diameter stenosis, % 87.0  11.3
Lesion features
Unprotected left main disease 26 (0.8)
Saphenous vein graft 1 (0.04)
Chronic total occlusions 76 (2.5)
Bifurcations 667 (21.7)
Restenotic lesions 69 (2.2)
Reference diameter 2.5 mm 180 (5.8)
Lesion length 20 mm 1,309 (42.5)
B2/C type 2,049 (66.5)
Procedural features
Total stent no. 3,748
No. of stents per patient 1.8  1.1
Average stent diameter, mm 3.05  0.44
Average stent length, mm 26.7  13.0
Direct stenting 1,965 (52.4)
Overlapping stents 658 (17.5)
Post-dilation 496 (13.2)
Intravascular ultrasound guidance 47 (1.3)
Data are expressed as mean SD or n (%).ere predictors of MACE.ngiographic outcomes. Angiographic follow-up was com-
leted in 974 (31.6%) lesions from 653 (31.7%) patients.
uantitative coronary angiography results at baseline, after
he procedure, and at follow-up are shown in Table 5.
n-stent and -segment late lumen loss were 0.21 0.39 mm
nd 0.21  0.35 mm, respectively. Binary restenosis rates
ere 3.8% in-stent and 6.7% in-segment.
iscussion
he present study, to our knowledge, is the first post-
arketing, multicenter registry of a biodegradable polymer-
ased SES. The results indicate that, although 80.5% of
ischarged patients received only 6 months or even shorter
eriods of dual antiplatelet treatment, the safety profile of
his novel DES when used in real-world practice is satis-
actory with low rates of MACE, overall stent thrombosis,
nd late stent thrombosis.
It has been widely accepted that DES can effectively
educe the need for TLR. However, several recent studies
ave suggested that first-generation DES could delay local
Table 3. Clinical Outcomes
n (%)
30-day outcomes (n  2,077)
Death 16 (0.77)
Cardiac 13 (0.63)
Noncardiac 3 (0.14)
Nonfatal MI 6 (0.29)
Urgent TLR 4 (0.19)
MACE 19 (0.91)
1-year outcomes (n  2,063)
Death 35 (1.7)
Cardiac 22 (1.1)
Noncardiac 13 (0.6)
Nonfatal MI 8 (0.4)
TLR 32 (1.6)
Percutaneous 31 (1.5)
Surgical 1 (0.05)
MACE 56 (2.7)
Non-TLR target vessel revascularization 2 (0.1)
18-month outcomes (n  2,062)
Death 39(1.9)
Cardiac 23 (1.1)
Noncardiac 16 (0.6)
Nonfatal MI 9 (0.4)
TLR 39 (1.9)
Percutaneous 38 (1.8)
Surgical 1 (0.05)
MACE 64 (3.1)
Non-TLR target vessel revascularization 4 (0.2)
Data are depicted as n (%).
MACEmajor adverse cardiac events; MImyocardial infarction; TLR target lesion revas-cularization.
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307essel healing and increase the risk of potentially fatal late
tent thrombosis (5,13–15), an adverse event that may be
ttributed to the durable polymer coatings of DES
8–11,15–20). Although prolonged dual antiplatelet ther-
py for at least 1 year after DES implantation was recom-
ended to address the increased risk of late stent throm-
osis (21), long-term dual antiplatelet therapy is associated
ith increased hemorrhagic events, financial burden, vari-
ble patient compliance and responsiveness, and other side
ffects. Therefore, new generation DES with bioabsorbable
olymer coatings or even bioabsorbable stent struts have
een recently developed. It is anticipated that those stents
ill result in comparable neointimal hyperplasia prohibition
nd fewer late complications compared with first-generation
ES.
In accordance with the experience with other SES, in this
tudy the Excel stent has efficiently reduced neointima
yperplasia and in-stent restenosis with an average 0.21 mm
Figure 1. Survival Free From Primary Outcomes at 18-Month Follow-Up
Kaplan-Meier estimates of survival free from major adverse cardiac events
(MACE) in studied populations.
Table 4. Stent Thrombotic Events at 18-Month Follow-Up
Thrombotic Events ARC Definite
Acute (24 h) 1
Subacute (24 h to 30 days) 4
Late (30 days to 1 year) 2
Very late (1 year) 0
Total 7 (0.34)
Data are depicted as n (%).ARC Academic Research Consortium.n-stent late lumen loss and an in-segment binary restenosis
ate of 6.7%. The higher mean late lumen loss in the present
tudy as compared with the 0.12 mm in-stent late lumen
oss that we had reported for the Excel stent in a single
enter pilot registry study (22) was likely due to the fact that
ngiographic follow-up was not mandatory in the present
tudy, which might have led to an increased proportion of
linically driven angiographic follow-up and thus an over-
stimated late loss. In the recently published LEADERS
Limus Eluted from A Durable Versus ERodable Stent
oating) trial, a biolimus-eluting stent with abluminal
iodegradable PLA polymer coatings has shown a similar
ate loss when compared with SES with durable polymer
0.13 mm vs. 0.19 mm) (23). Notably, both the present
tudy and the LEADERS trial had enrolled real-world
ll-comers including more than 80% off-label indications.
hose results suggest that a limus-eluting stent with ablu-
inal coated biodegradable PLA polymer is as effective as
ES with durable polymer in reducing restenosis. Thus, the
otential differences in pharmacokinetic release of the drug
etween the 2 kinds of DES have not lead to different effects
n restenosis prevention.
It is anticipated that the biodegradable PLA polymer
oatings in the Excel stent can be fully absorbed within 6 to
months and exert few adverse effects on vascular response
nd endothelialization. We hypothesized that 6-month dual
ntiplatelet therapy is enough after Excel stent implantation
egardless of baseline characteristics. In the present study,
0.5% of discharged patients discontinued clopidogrel treat-
ent within 6 months and the overall occurrence of stent
hrombosis was 0.87%; the rate of Academic Research
onsortium definite or probable stent thrombosis, in line
ith the definition of stent thrombosis in previous studies,
as 0.58%, which is similar to that in SES randomized trials
range: between 0% and 2.0%) (1,24–27) as well as that
n real-world registries (range: between 0.4% and 1.5%)
28–30). After the discontinuation of clopidogrel, the rate
f documented stent thrombosis was 0.19% for the present
tudy, which was substantially lower than that reported in
he BASKET-LATE (Late Clinical Events Related to Late
tent Thrombosis After Stopping Clopidogrel) study
2.6%) (5). These encouraging results indicate that the
C Probable ARC Possible Total
1 0 2 (0.10)
4 0 8 (0.38)
0 5 7 (0.34)
0 1 1 (0.05)
5 (0.24) 6 (0.29) 18 (0.87)AR
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308efinement of DES in coating biocompatibility by use of
iodegradable PLA coating, such as that present in the
xcel stent, might potentially serve as an appealing alterna-
ive to minimize the risk of late stent thrombosis, which
equires confirmation with randomized trials.
Several pilot studies had demonstrated the feasibility,
afety, and efficacy of biodegradable polymer-based DES in
elected patients (31–34). However, the validity of extrap-
lating those results to daily practice had remained uncer-
ain because the follow-up period of most studies were not
ong enough to elucidate the consequences after completed
egradation of a biodegradable polymer. In the present
tudy, the Excel stent has shown sustained excellent clinical
utcomes up to 18 months, which suggests the long-term
linical benefits of biodegradable polymer-based SES.
owever, issues must be addressed about the very low
ncidence of MACE and stent thrombosis in the present
tudy. First, patients with device failure, which may influ-
nce the long-term prognosis, were excluded in the present
tudy. Second, there are now several reports that suggest
hat the incidence of stent thrombosis is relatively low in
sian populations (30,35,36). The mechanisms of such
henomenon are unclear, but might be associated with
enetic specificity. Third, compared with the multicenter
-Cypher registry, the baseline clinical and angiographic
haracteristics of the present study were less complex,
epresented as lower incidences of diabetes, history of MI,
rior percutaneous coronary intervention, and fewer B2/C
ype lesions (29). These distinctions between the 2 studies,
lthough both enrolled all-comers, may reflect the different
atient cohort and percutaneous coronary intervention in-
ications between China and other countries, which may
esult in some differences in clinical outcomes. Finally, in
Table 5. Lesion Data Determined by Quantitative Coronary Angiography at
In-Segment
Pre-procedure
Reference vessel diameter, mm 2.77 0.47
Lesion length, mm 22.4 13.1
Diameter stenosis, % 73.5 15.1
Minimal lumen diameter, mm 0.74 0.45
Post-procedure
Reference vessel diameter, mm 3.19 0.45
Diameter stenosis, % 25.0 9.5
Minimal lumen diameter, mm 2.34 0.52
Acute gain, mm 1.60 0.55
Follow-up
Reference vessel diameter, mm 3.13 0.45
Diameter stenosis, % 30.0 14.6
Minimal lumen diameter, mm 2.13 0.59
Late lumen loss, mm 0.21 0.35
Binary restenosis, % 6.7omparison with randomized trials, the rate of TLR wasower in the present study, similar to most of the real-world
egistries, because the angiographic follow-up was not
andatory and there must be some patients with recurrent
schemia who do not undergo repeat intervention for
ifferent reasons.
tudy limitations. The present study is limited by the fact
hat it is a single arm, nonrandomized study. A head-to-
ead comparison with other DES are demanded to confirm
he efficacy and safety of biodegradable polymer-based SES.
oreover, post-procedure changes in cardiac biochemical
arker levels were not subjected to routine surveillance in
ome participating centers; therefore, non–Q-wave MI
ight have been underreported. However, most of the
nderreported MACEs were asymptomatic events that are
sually associated with less clinical significance than symp-
omatic events, suggesting that underreporting of MACEs
n the present study exerts limited impact on the
onclusions.
onclusions
he outcomes of the present study demonstrate satisfactory
fficacy and safety profiles for the Excel biodegradable
olymer-based SES in treating patients in real-world set-
ings, with low rates of MACE and stent thrombosis up to
8 months. The outcomes also suggest that 6 months of
ual antiplatelet therapy with clopidogrel and aspirin after
xcel stent implantation is safe and feasible.
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nd Post-Procedure and Follow-Up (n  974)
In-Stent Proximal Edge Distal Edge
— — —
— — —
— — —
— — —
— — —
14.3 4.7 12.1 7.8 16.5 9.1
2.74 0.44 3.0 0.59 2.39 0.58
2.0 0.50 — —
— — —
19.4 13.7 15.1 9.9 19.1 10.0
2.53 0.59 2.81 0.59 2.25 0.56
0.21 0.39 0.19 0.28 0.14 0.27
3.8 1.2 2.0Pre-a
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1
1
1
1
1
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1
1
1
2
2
2
2
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2
2
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2
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3
3
3
3
3
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